about
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcersA cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong KongCYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillationCost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial.Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children.Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.Pharmacoeconomic evaluation of warfarin pharmacogenomics.Antimicrobial stewardship programs - cost-minimizing or cost-effective?Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Disease Burden, Characteristics, and Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection in Hong Kong.Economic outcomes of influenza in hospitalized elderly with and without ICU admission.Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting.Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy.Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis.Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong.Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area.Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry.Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong.Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: a cost-effectiveness analysis.Meticillin-resistant Staphylococcus aureus bacteraemia in Hong Kong.Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong.Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Expectant, medical or surgical treatment for spontaneous abortion in first trimester of pregnancy: a cost analysis.Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.Surveillance-guided selective digestive decontamination of carbapenem-resistant Enterobacteriaceae in the intensive care unit: A cost-effectiveness analysis.Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.The all-powerful and 'happy' drug: the use of steroids among primary care doctors in Hong Kong.The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.
P50
Q28142472-8889F54C-617C-4DFF-9D8E-9DD0F188A82DQ28730856-40AFA8D8-080C-4956-8FD8-FA5763EE120FQ33613593-33989A16-2036-47D6-B99F-921E8848F5F6Q33619422-B9C41764-5952-4ED4-AD2B-1021FEFB9FBCQ34321590-8FC16014-24B6-4D5B-AA2F-E53A19064795Q34582189-412A8B12-2F3C-4991-AC02-53C917C2C661Q35826483-7C36873F-CD4E-4A59-91A9-063CE0C117C8Q35826999-4DAB9482-CD92-4370-B959-7D3D6FCF834FQ35827850-DB6C05B7-B7DA-40FA-A300-235D31634B6FQ35886955-A243C31A-DADA-4A18-8CD6-85AA0B03DA5FQ36231674-4B4EA0F4-538F-48AC-A71F-A70AB9E571E0Q37595758-09F73B7B-3094-4D72-8927-C49A4860E983Q37828165-77A14CBC-18C2-4518-9A03-170522513FF4Q38261509-E105DD99-4813-4335-B355-1F449AF7905FQ38347110-C8A5346A-B4F6-49B2-93B1-5B9AA593D2AFQ38673682-66AA207B-662D-459D-845E-76118D1AEDCBQ39292144-CBB97F95-18CD-4328-858B-9B652399E959Q40105670-443C4F9F-B1AE-4B2B-9A69-63EE38C8EA8FQ40189470-B5654E99-61D7-45A0-B711-001BFA9504D1Q40522242-9CA10A2B-F1B5-430A-B879-F587854EBBE2Q40713908-8F0B72DD-B52A-4DF7-B21E-02D71A13F0FDQ40859539-E4197A47-854A-47FD-8298-CBF0BACCCC40Q41389003-CBF490BF-F6CF-409C-ABAC-5DF2D90FA5BBQ41554567-4EAEA6D3-EDD2-4884-8951-0638E7158A21Q43172927-DF04423F-62AF-4133-937F-78D53A11FF36Q43650359-0EF7BBC2-10A2-468B-BBC0-BAD31A1545AFQ44154839-878C94D4-AF2C-4A37-9545-8984D8210AC7Q44525413-0B98A5D1-F9B0-4FEB-BB39-F6C1623548EFQ45186105-F6D74ECB-FA4E-4C85-9E0D-4C1DED5AFE52Q45942815-D1263B40-AFFE-4F22-A011-0A176477CA79Q46568121-A11540D2-9604-4A1A-BC44-BE0FBB4D46C5Q48165705-9FCB1B9C-E075-4B03-8B66-7D91D9CF334BQ48910934-950A2CDD-50A8-43BA-A151-8AA10414C827Q50152430-1128A9AF-1942-4753-9CFF-E97B24790846Q50854235-AA85CA05-C959-4616-ACB7-A6770E6CB2EEQ50932289-977AC448-AF7D-47F5-80E2-F8F34CC16645Q50950032-FADCC829-04FB-468A-8F76-207FC77D8EFAQ50952318-17D8F690-30A4-461C-8AEB-737440189829Q51808865-A8091092-8171-47CB-B198-B511DBA8B11BQ51990344-B01CA25E-34BF-46C2-8560-F22367F8067B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joyce H You
@ast
Joyce H You
@en
Joyce H You
@es
Joyce H You
@nl
type
label
Joyce H You
@ast
Joyce H You
@en
Joyce H You
@es
Joyce H You
@nl
prefLabel
Joyce H You
@ast
Joyce H You
@en
Joyce H You
@es
Joyce H You
@nl
P106
P31
P496
0000-0002-5763-7403